2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Bacterial, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4460 A patient-and observer-informed Delphi framework for selecting clinical outcome assessment reporter types for TTP clinical trials

Oluwatoyosi Onwuemene, MD, MS, Laura Mkumba, MSc2, Brian Adkins, MD3, Benjamin Tillman, MD4, Jamila Minga, PhD5, Jada Green, MPH6, Fiorella Guerrero Calle, PhD7, Theresa Coles, PhD8
1 Duke University School of Medicine, Durham, North Carolina, United States
2 Duke University School of Medicine, Durham, North Carolina, United States
3 University of Texas Southwestern Medical Center, Dallas, Texas, United States
4 Vanderbilt University Medical Center, Nashville, Tennessee, United States
5 Duke University School of Medicine, Durham, North Carolina, United States
6 Duke University School of Medicine, Durham, North Carolina, United States
7 Duke University School of Medicine, Durham, North Carolina, United States
8 Duke University School of Medicine, Durham, North Carolina, United States

INTRODUCTION: Cognitive function is an important health-related quality-of-life domain for individuals with immune thrombotic thrombocytopenic purpura (TTP). In TTP clinical studies, cognitive function has been assessed using clinical outcome assessments (COAs) that vary widely in the cognitive domains assessed and in reporter type (Patient-reported (PRO), observer-reported (ObsRO), clinician-reported (ClinRO), or performance-based (PerfO)). This heterogeneity limits cross-study comparisons and interpretation of treatment effects. Therefore, building on a patient- and observer-informed conceptual model developed within the NIH-funded THINK-TTP study, we conducted a targeted literature review and a modified reactive Delphi panel to develop consensus-based recommendations for selecting COA reporter types for assessing cognitive function in TTP clinical trials.

METHODS: The study used a targeted review of candidate COAs and a modified reactive Delphi consensus process. An 11-member multidisciplinary panel with 5 or more years of relevant expertise in TTP and cognition reviewed and refined a patient- and observer- informed conceptual model comprising four domains: language, memory, complex attention/executive function, and cognitive inefficiency. During the initial panel meeting, members conducted an exploratory vote on preferred reporter types. A targeted review then identified and characterized candidate COAs according to reporter type, domain coverage, format, feasibility, and available supporting evidence. Eligible COAs assessed at least one conceptual-model domain, were potentially feasible for clinical-trial use, and had sufficient information for characterization. Because the review did not identify a candidate COA covering all four domains, the panel reconvened to review the findings and conduct iterative consensus voting on reporter types. The meetings were conducted virtually via Zoom and voting was anonymous using Qualtrics. Iterative voting rounds continued until consensus was reached or no further change was proposed. Consensus was defined a priori as 80% or greater agreement.

RESULTS: The targeted review identified 57 candidate COAs, including 40 PerfOs, 13 PROs, and 4 ObsROs. No ClinROs were identified. Thirty-one candidate COAs were excluded because of lack of alignment with the conceptual model, decreased likelihood of detecting mild cognitive difficulties, screening-only design, limited applicability to the target population, or recall periods exceeding one year. Of the 26 COAs considered relevant, none assessed all four conceptual-model domains. In the initial vote, the panel reached consensus for a PRO for cognitive inefficiency (10/11, 91%). Following review of the candidate COAs and moderated discussion, consensus was reached for a PRO for language (10/11, 91%), both a PRO (11/11, 100%) and PerfO (10/11, 92%) for memory, and a PerfO for complex attention/executive function (9/11, 82%). The resulting framework favored PROs for language and cognitive inefficiency, a PerfO for complex attention/executive function, and complementary PRO and PerfO assessment for memory.

CONCLUSION: A patient- and observer- informed, multidisciplinary consensus process supported a multidimensional approach to assessing cognitive function in TTP clinical trials. The recommendations link cognitive domains with preferred COA reporter types. This framework provides a foundation for selection of COAs that are fit-for-purpose. With the selected COAs, future studies should perform TTP-specific evaluation of content validity, feasibility, reliability, responsiveness, and interpretability.

Oluwatoyosi Onwuemene, MD, MS: Sanofi - Honoraria; Sanofi - Membership on a Board/Advisory Committee